Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
3M Stock: Dividend Likely Cut In Half
May 1, 2024
Amazon Q1 Review: Best Of Big Tech Bunch
April 30, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BHVN Stock News and Mentions of Biohaven Pharmaceutical Holding Company Ltd. Stocktwits
Updated: May 2, 2024 (11:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Biohaven Pharmaceutical Holding Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Biohaven Pharmaceutical Holding Company Ltd. (BHVN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Biohaven Pharmaceutical Holding stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
May 1, 2024 (22:30) / "Motley Fool" (by Motley Fool Transcribing)
Pfizer ( PFE ) Q1 2024 Earnings Call Transcript
PFE earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
May 1, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Q1 Earnings & Sales Top, EPS Guidance Raised
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
In Article Trend: Neutral
April 30, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
The sun could be peeking through the dark clouds for Pfizer.
In Article Trend: Neutral
April 29, 2024 (16:12) / "Zacks Commentary" (by Kinjel Shah)
Here's How to Play Pfizer ( PFE ) Stock Ahead of Q1 Earnings
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
In Article Trend: Neutral
April 26, 2024 (11:36) / "Benzinga" (by Avi Kapoor)
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying - Biohaven ( NYSE:BHVN )
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
In Article Trend: Somewhat-Bullish
April 25, 2024 (12:05) / "PR Newswire" (by Freedom Biosciences)
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant ... PR ...
In Article Trend: Neutral
April 13, 2024 (13:00) / "PR Newswire" (by Biohaven Ltd.)
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology ( AAN ) Annual Meeting and Provides Other Business Updates
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of ... PR ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Pfizer's ( PFE ) New Drugs Provide a Boost to 2024 Sales?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
In Article Trend: Somewhat-Bullish
March 27, 2024 (13:31) / "Benzinga" (by Vandana Singh)
Why Is Altimmune Stock Trading Higher Today? - Altimmune ( NASDAQ:ALT )
Wednesday, Altimmune Inc ALT said the body composition study of pemvidutide showed lean mass preservation, with 25.5% of weight loss derived from lean mass with 74.5% of weight loss from adipose tissue, comparable to the effects historically associated with diet and exercise.
In Article Trend: Neutral
March 26, 2024 (17:48) / "Benzinga" (by Vandana Singh)
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven ( NYSE:BHVN )
Monday, Biohaven's BHVN CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company's experimental obesity drug. Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S's NVO and Eli Lilly And Co's LLY popular GLP-1 drugs.
In Article Trend: Neutral
March 23, 2024 (10:45) / "Motley Fool" (by Keith Speights)
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:30) / "Motley Fool" (by David Jagielski)
Is Pfizer Stock a Millionaire Maker?
A couple of years ago, Pfizer's shares may have seemed like a sure thing. That may not be the case anymore.
In Article Trend: Neutral
March 15, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website